share_log

Inhale-3 Study Results to Be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association's 84th Scientific Sessions

Inhale-3 Study Results to Be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association's 84th Scientific Sessions

Inhale-3研究结果将在美国糖尿病协会第84届科学会议期间的周六，6月22日，举行为期90分钟的研讨会上宣布。
曼恩凯德生物医疗 ·  06/05 00:00
  • 17-week endpoint results comparing Afrezza head-to-head with multiple daily injections (MDI) and insulin pumps
  • INHALE-3 Study Protocol Chair Dr. Irl. B. Hirsh joined by investigational team to deliver presentation moderated by Jaeb Center founder Dr. Roy W. Beck
  • 比较Afrezza在17周的终点结果，与多次日常注射(MDI)和胰岛素泵进行头对头的比较。INHALE-3研究协议主席Irl. B. Hirsh与调查团队一起交流报告，由Jaeb中心创始人Roy W. Beck博士主持。
  • 2014年6月5日美国康涅狄格州丹伯里和加州WESTLAKE VILLAGE，曼恩凯德生物医疗公司(NASDAQ:MNKD)，专注于开发和商业化治疗内分泌和孤儿肺部疾病的创新吸入治疗产品和设备，宣布INHALE-3研究的17周终点结果将于6月22日星期六在美国糖尿病协会(ADA)的84次科学会议期间通过90分钟的研讨会和直播进行展示。Irl B. Hirsh博士和调查团队将进行报告，并由Jaeb中心创始人Roy W. Beck博士主持。

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced that the 17-week endpoint results from the INHALE-3 study will be presented during a 90-minute symposium and livestream on Saturday, June 22, at the American Diabetes Association's (ADA) 84th Scientific Sessions. The presentation will be delivered by INHALE-3 Study Protocol Chair Dr.Irl B. Hirsh and the investigational team and will be moderated by Jaeb Center founder Dr. Roy W. Beck.

曼恩凯德生物医疗（Nasdaq: MNKD）是一家专注于开发和商业化用于内分泌和孤儿肺部疾病患者的创新吸入治疗产品和设备的公司，宣布将在美国糖尿病协会（ADA）84次科学研讨会上进行为期90分钟的研讨会和现场直播，介绍INHALE-3研究17周终点结果。th研究协议主席Irl B. Hirsh博士及调查团队将作介绍，Jaeb研究中心创始人Roy W. Beck博士担任主持人。

"We are excited for the first read-out of results from the largest post-market clinical trial MannKind has conducted with Afrezza in the last 10 years," said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. "The results will speak to the common question about Afrezza: 'How does inhaled insulin fare when compared head-to-head with usual care?' The full 30-week results of INHALE-3 will be available later this year."

"我们很高兴看到曼恩凯德生物医疗公司在过去的10年中进行了使用Afrezza的最大后市临床试验的首次结果发布，"曼恩凯德公司的首席执行官Michael Castagna表示:"结果将回答一个普遍的问题，即Afrezza在与常规治疗进行头对头比较时的表现如何?"INHALE-3的完整30周结果将在今年晚些时候公布。"

Title:
 The Efficacy and Safety of Inhaled Insulin Used with Insulin Degludec Compared with Automated Insulin Delivery or Multiple Daily Injections in Adults with Type 1 Diabetes
Date: Saturday, June 22, 2024
Times: 8:00-9:30 AM (ET) with topics/presenters to include:
  • Inhaled Insulin's History and Study Rationale – Dr. Halis Akturk
  • Study Methods & Participant Baseline Characteristics – Dr. Yogish Kudva
  • Study Results I: Comparison of Inhaled Insulin vs. Rapid Acting Analogue Insulin in Users of AID or
  • MDI During Standardized In-Clinic Meal Challenge –Dr. Ruth S. Weinstock
  • Study Results II: Primary Efficacy, Safety, and Quality of Life Outcomes – Dr. Carol J. Levy
  • Study Results III: Effect of Inhaled Insulin-Degludec Compared with AID and in Subgroups According
  • to Participant Characteristics – Dr. Grazia Aleppo
  • Critique of Study Design and Results – by Dr. Irl B. Hirsch
  • Use of Afrezza in Clinical Practice – by Dr. Thomas Blevins
  • Question and Answer Session – Moderated by Dr. Roy W. Beck
Location: W320 Chapin Theatre at the Orange County Convention Center (+livestream)
Livestream:
 Please refer to https://professional.diabetes.org/scientific-sessions for access details
标题：
 吸入胰岛素与注射胰岛素Degludec联用的安全性和有效性比较与自动注射胰岛素或多次日常注射在1型糖尿病成人中的应用
日期： 2024年6月22日星期六
时间: 8:00-9:30 AM (ET)，讨论话题/发言人包括:
  • 吸入胰岛素的历史和研究基础 - Halis Akturk博士
  • 研究方法和参与者基线特征 - Yogish Kudva博士
  • 研究结果I:吸入胰岛素与AID或MDI用于标准临床餐挑战的快速作用类似胰岛素的比较- Ruth S. Weinstock博士
  • 研究结果II:主要功效、安全和生活质量结果 - Carol J. Levy博士
  • 研究结果III:与参与者特征相符的吸入胰岛素Degludec与AID的比较 - Grazia Aleppo博士
  • 研究设计和结果的批评 - Irl B. Hirsch博士
  • 临床实践中Afrezza的使用 - Thomas Blevins博士
  • 问题和答案环节 - 由Roy W. Beck博士主持
  • 在临床实践中使用Afrezza-Thomas Blevins博士
  • 由方正证券公司(NASDAQ:MNKD)宣布INHALE-3研究的17周终点结果将于2024年6月22日星期六在美国糖尿病协会(ADA)的84次科学会议期间展示。
位置： W320 Chapin剧院位于Orange County Convention Center（+现场直播）
现场直播：
 请访问https://professional.diabetes.org/scientific-sessions获取访问详细信息。https://professional.diabetes.org/scientific-sessions获取访问详细信息。

MannKind will host booth# 1307 in the Exhibit Hall throughout the Scientific Sessions as well. Members of MannKind's Clinical Education Team will be available for scientific exchange in the medical section of the booth.

曼恩凯德生物医疗将在科学会议期间的展厅1307展台设立展台，并在展台的医疗部分提供其临床教育团队的科学交流服务。

About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.

曼恩凯德生物医疗公司（Nasdaq：MNKD）专注于为那些患有内分泌和孤儿肺病的患者开发和商业化创新吸入治疗产品和设备。
我们致力于利用我们的配方能力和设备工程的技术，减轻糖尿病，非结核分枝杆菌（NTM）肺病，肺纤维化和肺动脉高压等疾病的负担。我们的标志性技术——干粉配方和吸入设备——可以快速，方便地向肺的深处输送药物，从而在目标疾病的治疗方面产生局部或进入系统循环的作用，具体取决于治疗目标。

We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.

在整个团队以及全国范围内合作的曼尼海特人的激情下，我们致力于实现让人们控制自己的健康和自由自在地生活的使命。

With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.

mannkindcorp.com了解更多信息，以及关注我们的消息。

Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, X or Instagram.

请访问mannkindcorp.com了解更多信息，关注我们。LinkedIn, Facebook, X或。Instagram.

Forward-Looking Statements
This press release contains forward-looking statements about the release of data from a clinical study that involve risks and uncertainties. Words such as "believes", "anticipates", "plans", "expects", "intends", "will", "goal", "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that continued testing of an investigational drug product may not yield successful results or results that are consistent with earlier testing, and other risks detailed in MannKind's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent periodic reports on Form 10-Q and current reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

前瞻性声明
本新闻稿包含有关临床研究数据发布的前瞻性声明，涉及风险和不确定性。旨在找出前瞻性声明的词语包括“相信”、“预期”、“计划”、“期望”、“打算”、“将会”、“目标”、“潜在”等类似表达方式。这些前瞻性陈述是基于MannKind目前的期望，实际结果和事件发生的时间可能会因各种风险和不确定性而与这些前瞻性陈述有所不同，包括但不限于继续测试一种研究中的药物产品可能不会产生成功的结果或与先前的测试结果不一致，以及其他在MannKind在证券交易委员会备案的文件中，包括其年度报告10-K，以及随后提交的周期性报告10-Q和当前提交的8-K报告中详细说明的风险。请注意，这些前瞻性陈述仅截至新闻稿日期具有资格，并受到该警示性声明的全部限制，MannKind不承担更新任何前瞻性陈述以反映此后事件或情况的义务。

AFREZZA and MANNKIND are registered trademarks of MannKind Corporation.

AFREZZA和曼恩凯德均为MannKind Corporation的注册商标。

For MannKind: Christie Iacangelo, Corporate Communications (818) 292-3500 Email: media@mnkd.com  Rose Alinaya, Investor Relations (818) 661-5000 Email: ir@mnkd.com
曼恩凯德生物医疗公司媒体联系人Christie Iacangelo (818) 292-3500 电子邮件 media@mnkd.com。media@mnkd.com投资人关系部门联系人Rose Alinaya，电话：(818)661-5000 邮箱：ir@mnkd.com

Primary Logo

Source: MannKind

来源：曼恩凯德生物医疗

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发